E.g., 10/16/2019
E.g., 10/16/2019

bioMérieux and ExonHit Therapeutics Extend their Strategic Collaboration

13 October, 2005

bioMérieux and ExonHit announced today that they signed an agreement to extend their collaboration for six years for the discovery and development of new blood diagnostics in the area of early cancer detection.

DiagnoSwiss and bioMérieux announce that they have signed an exclusive license agreement for the development and use of DiagnoSwiss electrochemical microchips in human in vitro diagnostics

27 July, 2005

Monthey (Switzerland) – bioMérieux and DiagnoSwiss announced today that DiagnoSwiss has granted bioMérieux with an exclusive worldwide license under the patent rights of DiagnoSwiss relating to the development, manufacturing and marketing of electrochemical microchips in the field of human in vitro diagnostics.

Hepanostika® HBsAg Ultra – New “ultra”-sensitive test for Hepatitis B infection from bioMérieux

05 July, 2005

bioMérieux, a world leader in the field of in vitro diagnostics, announces the launch of its new microelisa assay for the detection of hepatitis B surface antigen. Hepanostika® HBsAg Ultra is officially presented at the XV European Regional Congress of the International Society of Blood Transfusion (ISBT) currently being held from July 2-6 in Athens, Greece.

Hospices Civils de Lyon and bioMérieux inaugurate a joint immunogenomics and inflammation unit

23 June, 2005

Hospices Civils de Lyon (HCL) and bioMérieux will inaugurate today the “HCL-bioMérieux” joint unit dedicated to research in immunogenomics and inflammation. The unit is headed by Prof. Pierre Miossec and Bruno Mougin.

MRSA ID - bioMérieux’s latest contribution to the fight against nosocomial infections

25 May, 2005

A world leader in the field of in vitro diagnostics, bioMérieux SA announces the launch of a new product for rapid, reliable identification of Methicillin-Resistant Staphylococcus aureus, a common cause of nosocomial infections.

Roche Diagnostics and bioMérieux announce that Roche has granted non exclusive rights for cardiac markers NT-proBNP to bioMérieux

29 April, 2005

Roche Diagnostics and bioMérieux announced today, that bioMérieux has been granted a nonexclusive license agreement under the patent rights of Roche Diagnostics relating to the development, manufacturing and marketing of immunoassays that detect a key cardiac marker of congestive heart failure and acute coronary syndrome.

Affymetrix and bioMérieux Extend Their Agreement on GeneChip® Technology to Breast Cancer Diagnostics

05 April, 2005

The agreement includes an option for bioMérieux to use Affymetrix GeneChip® technology in other cancer areas.

NucliSens® miniMAG™, bioMérieux’s next generation nucleic acid extraction platform is now available as CE-IVD approved platform

25 March, 2005

bioMérieux announces the introduction of the NucliSens miniMAG and NucliSens Magnetic Extraction Reagents as CE-IVD marked products. A major actor in the field of in vitro diagnostics (IVD), bioMérieux thereby reinforces its commitment to quality and fulfilment of the most stringent regulatory requirements.

Chinese Academy of Medical Sciences and bioMerieux join resources to fight emerging pathogens

11 March, 2005

The Chinese Academy of Medical Sciences and bioMérieux announce that they have signed a strategic teaming agreement, aiming at initiating R&D projects in the fields of emerging pathogens. The aim of the project, signed on March 10th, is the creation of a joint Research Lab in Beijing, interacting with Chinese Academy of Medical Sciences.

B·R·A·H·M·S AG and bioMérieux SA sign a non-exclusive agreement on the use of Procalcitonin

01 March, 2005

B·R·A·H·M·S AG and bioMérieux SA have announced the signature of a non-exclusive agreement on the use of Procalcitonin as a diagnostic marker for severe bacterial infections

Pioneering Diagnostics